OBJECTIVE: This study was conducted to determine whether the human papillomavirus (HPV) genotype by the HPV DNA chip test (HDC) is predictive of residual or recurrent high-grade cervical intraepithelial neoplasia (CIN) 2-3 following a loop electrosurgical excision procedure (LEEP). STUDY DESIGN: Between January 2001-February 2007, 672 patients with CIN2-3 were treated by a LEEP and followed up with cytology, the hybrid capture II assay, and the HDC. RESULTS: A total of 37 (5.5%) patients developed a recurrence, and those who developed a recurrence tested positive for the same high-risk (HR) HPV genotype before and after the LEEP. The same HR-HPV genotype by the HDC during the follow-up had a sensitivity and negative predictive value of 100% for detecting residual/recurrent disease. Persistent HPV-16 and HPV-18 were significantly associated with recurrent CIN2-3 (P < .05). CONCLUSION: Persistent infection with the same HR-HPV genotype, especially HPV-16 and HPV-18, should be considered a risk factor for developing residual/recurrent CIN2-3. Copyright (c) 2010 Mosby, Inc. All rights reserved.
OBJECTIVE: This study was conducted to determine whether the human papillomavirus (HPV) genotype by the HPV DNA chip test (HDC) is predictive of residual or recurrent high-grade cervical intraepithelial neoplasia (CIN) 2-3 following a loop electrosurgical excision procedure (LEEP). STUDY DESIGN: Between January 2001-February 2007, 672 patients with CIN2-3 were treated by a LEEP and followed up with cytology, the hybrid capture II assay, and the HDC. RESULTS: A total of 37 (5.5%) patients developed a recurrence, and those who developed a recurrence tested positive for the same high-risk (HR) HPV genotype before and after the LEEP. The same HR-HPV genotype by the HDC during the follow-up had a sensitivity and negative predictive value of 100% for detecting residual/recurrent disease. Persistent HPV-16 and HPV-18 were significantly associated with recurrent CIN2-3 (P < .05). CONCLUSION: Persistent infection with the same HR-HPV genotype, especially HPV-16 and HPV-18, should be considered a risk factor for developing residual/recurrent CIN2-3. Copyright (c) 2010 Mosby, Inc. All rights reserved.
Authors: Anne F Rositch; Heidi M Soeters; Tabatha N Offutt-Powell; Bradford S Wheeler; Sylvia M Taylor; Jennifer S Smith Journal: Gynecol Oncol Date: 2014-01-07 Impact factor: 5.482
Authors: Sarah R Hoffman; Tam Le; Alexandre Lockhart; Ayodeji Sanusi; Leila Dal Santo; Meagan Davis; Dana A McKinney; Meagan Brown; Charles Poole; Corinne Willame; Jennifer S Smith Journal: Int J Cancer Date: 2017-02-27 Impact factor: 7.396
Authors: Roland Matthews; Andres Azuero; Senait Asmellash; Earl Brewster; Edward E Partridge; Chandrika J Piyathilake Journal: Int J Womens Health Date: 2011-07-12
Authors: Fabio Bottari; Anna D Iacobone; Rita Passerini; Eleonora P Preti; Maria T Sandri; Clementina E Cocuzza; Devin S Gary; Jeffrey C Andrews Journal: Obstet Gynecol Date: 2019-09 Impact factor: 7.623